StemCell Therapy

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2019.

We achieved another quarter of strong revenue and earnings growth as we continue to realize the benefits of our sustained investment in research and development and our focus on commercial execution, said Kenneth C. Frazier, chairman and chief executive officer, Merck. We are confident that the investments we are making now will allow us to convert cutting-edge science into medicines and vaccines of great benefit to patients and value to shareholders.

Financial Summary

$ in millions, except EPS amounts

Third Quarter

2019

2018

Change

ChangeEx-Exchange

Sales

$12,397

$10,794

15%

16%

GAAP net income1

1,901

1,950

-3%

-3%

Non-GAAP net income that excludes certain items1,2*

3,873

3,178

22%

22%

GAAP EPS

0.74

0.73

1%

1%

Non-GAAP EPS that excludes certain items2*

1.51

1.19

27%

27%

*Refer to table on page 9

GAAP (generally accepted accounting principles) earnings per share assuming dilution (EPS) were $0.74 for the third quarter of 2019. Non-GAAP EPS of $1.51 for the third quarter of 2019 excludes a $982 million charge for the acquisition of Peloton Therapeutics, Inc. (Peloton), a $612 million pretax intangible asset impairment charge, other acquisition- and divestiture-related costs, restructuring costs and certain other items. Year-to-date results can be found in the attached tables.

Pipeline Highlights

Oncology

Merck continued to advance the development programs for KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy; Lynparza (olaparib), a PARP inhibitor being co-developed and co-commercialized with AstraZeneca; and Lenvima (lenvatinib mesylate), an orally available tyrosine kinase inhibitor being co-developed and co-commercialized with Eisai Co., Ltd. (Eisai).

KEYTRUDA

Lynparza

Lenvima

Other Pipeline Highlights

Third-Quarter Revenue Performance

The following table reflects sales of the companys top pharmaceutical products, as well as sales of animal health products.

Third Quarter

2019

2018

Change

Change Ex-Exchange

Total Sales

$12,397

$10,794

15%

16%

Pharmaceutical

11,095

9,658

15%

16%

KEYTRUDA

3,070

1,889

62%

64%

GARDASIL / GARDASIL 9

1,320

1,048

26%

27%

JANUVIA / JANUMET

1,311

1,490

-12%

-11%

PROQUAD, M-M-R II and

VARIVAX

623

525

19%

19%

BRIDION

284

217

31%

32%

ISENTRESS / ISENTRESS HD

250

See more here:
Merck Announces Third-Quarter 2019 Financial Results - Business Wire

This entry was posted on November 3, 2019 at 12:45 am and is filed under Stem Cell Negative. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |